Assessment of right ventricular (RV) performance can be a challenge for clinicians and researchers, especially in the diseased heart. In their study on pulmonary arterial hypertension (PAH) in pediatric patients, Yang et al. sought to identify a quantitative measure to predict disease progression and to assist treatment planning. 1 The authors defined a potential biomarker (based on MRI and right heart catheterization data) that appears to correlate with clinical worsening, and outperforms several other metrics studied. During follow-up for a period from 1 to 10 years since diagnosis, an upward trend of the new biomarker was found for patients with clinical worsening (N ¼ 8) compared with a well-defined stable subgroup (N ¼ 9).
Like other investigators, the authors choose stroke work (SW) as a starting point but noted that, in two situations, SW may numerically be equal but clinically not the same, even after indexation (i) for body surface area (BSA). In good approximation, SW is obtained by multiplying the pertinent pressure difference (ÁP, Fig. 1(a) ) with the corresponding volume difference, stroke volume (SV). 2 This method is an accepted alternative for the more rigorous integration of the area within the pressure-volume (PV)-loop as applied by the authors.
Obviously, there are many combinations of ÁP and SV that yield the same SW. To accurately capture differences in physiology, the authors introduced what they call penalized SW by dividing SW by ejection fraction (EF). However, EF has shortcomings similar to those of SW in the sense that any given value is not unique. 2 Also, two patients can differ in terms of pathophysiology, but still have the same EF and SW, because matched alterations of ÁP can compensate for RV volume changes. Statisticians warn against problems involved with ratios. 3 In fact, upon dividing SW by the ratio EF, the SV cancels out, implying that the newly defined biomarker is not purely reflecting SW. Interestingly, the proposed penalized metric ( Fig. 1(a) depends only on the end-diastolic volume index (EDVi) and on ÁP, however precisely defined:
where ÁP can be regarded as RV end-systolic pressure (ESP) or any appropriate approximation such as RV mean systolic pressure minus mean RV diastolic pressure. 2 The proposed metric consists of the traditional SWi (¼ÁP * SVi) plus an extra component X equal to (ÁP * ESVi), where end-systolic volume index ESVi ¼ EDVi-SVi. Based on figure 2 in Yang et al., 1 the true SW ranges from approximately 800 to 5000 mmHgÁmL, implying that X is substantial in many cases, and certainly in the clinically most relevant target group of PAH patients. 1 Obviously, RVSW EF is not unique, because many combinations of EDVi and ÁP yield the same area. Subdivision in two portions, namely reflecting SW (orange) and the remaining area bounded by end-systolic volume index (ESVi), respectively, opens a route to connect to interpretation in terms of physiology by considering the broken line, which refers to end-systolic elastance (Emax). Emax is defined as ESP/(ESVi-Vo), where ESP is end-systolic pressure, and Vo is an extrapolated intercept. The triangular area under the Emax line added to SW is the PVA. This sum reflects a basic component of myocardial oxygen consumption. Note that the triangular area contributing to PVA is half of the area defined by RVSW EF after subtraction of the contribution by SW.
Basically the new biomarker is composed of a rectangular PV-area that includes SW ( Fig. 1(a)) , where the precise contours of the PV-loop become irrelevant by virtue of its definition. Moreover, deterioration of RV function caused by increasing ÁP and/or EDVi implies that the relative contribution of SW to RVSW EF becomes less important as time progresses. Indeed, larger values for ÁP and EDVi contribute to the value found for X, which equals RVSW EF minus SWi. Therefore, it is of paramount interest to analyze, and possibly interpret, the area X, which often dominates the impact of the newly introduced biomarker RVSW EF .
Decades ago, physiologists introduced the concept of end-systolic elastance (Emax) as an insightful description ( Fig. 1(b) ) with which to analyze ventricular function, which idea was also incorporated by the authors in their appendix. 1 Earlier investigations on Emax concerned animal studies, 4 and also clinical applications involving the RV. 5 The elastance concept offers an attractive tool to interpret the reported findings by establishing a relationship with myocardial oxygen consumption (MVO 2 ). To utilize this type of analysis based on energetics, we consider half of the area of RVSW EF NOT occupied by actual SW, and given by the triangular area in Fig. 1(b) . This triangular area (being 0.5 X) added to SW yields the pressure-volume area (PVA), and has been related to MVO 2 ( Fig. 1(b) ). 4, 5 Although the precise extent of the volume intercept (Vo) of the end-systolic elastance concept requires further clarification, this route may lend physiologic interpretation to the approach proposed by Yang et al. 1 In their lumped parameter model, the authors apply the Runge-Kutta method to obtain SW, while, for simplicity, we employ a more rectangular contour permitting direct multiplication of SV and ÁP. Indeed, the integral of ÁP * dV over the range of SV divided by SV is the average ÁP of the PV-loop. Thus, their formula decomposes to ÁP * EDVi, and, therefore, the shape of the PV-loop becomes irrelevant. The authors found a 7% difference between two methods to derive SW acceptable, and our approximation may well be within this limit when judging their figure 2. 1 Besides, the extra area X introduced by the authors is determined by ESVi and the choice of ÁP (Fig. 1(b) ) and independent of the approach preferred to obtain SW. As the authors emphasize in the legend of their figure 2, 1 the PV-loops for patients who clinically worsened tended to be generally larger and rightward. This means that both an increase of ÁP (or PAP for that matter) and elevation of EDVi point to a more severe disease state. Interestingly, multiplication of these two components yields the rectangular area that we emphasize for two examples in Fig. 1(a) ). Given a particular ÁP level, PVA is essentially determined by SVi and 0.5 * ESVi, assuming that Vo can be neglected (Fig. 1(b) ). ESVi is, in turn, inversely and nonlinearly related to EF, as demonstrated for the RV. 6, 7 We conclude that, rather than the isolated value of SW, even when obtained by a lumped parameter model, the ESVi is a dominant component of the proposed RVSW EF , especially in worsening PAH states. Total RVSW EF is determined by the area subtended by ÁP and RV EDVi ( Fig. 1(a) ). Selection of ÁP is not critical, as proportional relationships between systolic, diastolic, and mean PAP have been documented in health and RV disease. 8 Thus, the practical impact of the biomarker may be based on the fortunate product of two variables (namely ÁP and EDVi), which each independently already reflect disease severity in PAH (as specified in their legend to figure 2).
1 Importantly, the temporal trajectory followed by {EDVi,ÁP} as the disease process develops may be clinically relevant. Finally, RVSW EF suffers from the same shortcoming as initially noted for SW. Indeed, many combinations of ÁP and EDVi may yield the same value for the freshly introduced metric. We favor a representation in the PV domain ( Fig. 1(c) ), rather than the combination of ÁP and EDVi into a single number (namely RVSW EF ) as created by multiplication.
